References for Spring Worcester Medicine

Innovations in Education and Training to Improve Perinatal Mental Health by Martha Zimmermann, PhD; Anna R. Whelan, MD, FACOG; Tiffany A. Moore Simas, MD, MPH, MEd, FACOG; and Nancy Byatt, DO, MS, MBA, DFAPA, FACLP

[1]        S. Trost et al., “Pregnancy-Related Deaths: Data from Maternal Mortality Review Committees in 36 States, 2017-2019,” Education, vol. 45, no. 10, pp. 1-0, 2022.

[2]        K. B. Kozhimannil, C. M. Trinacty, A. B. Busch, H. A. Huskamp, and A. S. Adams, “Racial and ethnic disparities in postpartum depression care among low-income women,” (in eng), Psychiatr Serv, vol. 62, no. 6, pp. 619-25, Jun 2011, doi: 62/6/619 [pii]

10.1176/appi.ps.62.6.619.

[3]        “Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 4,” (in eng), Obstet Gynecol, vol. 141, no. 6, pp. 1232-1261, Jun 1 2023, doi: 10.1097/aog.0000000000005200.

[4]        “Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum No. 5,” Obstet Gynecol, vol. 141, no. 6, pp. 1262-1288, 2023.

[5]        N. Byatt et al., “Effectiveness of two systems-level interventions to address perinatal depression in obstetric settings (PRISM): an active-controlled cluster-randomised trial,” The Lancet Public Health, vol. 9, no. 1, pp. e35-e46, 2024.

 

 

 

The Black Maternal Health Crisis, Black Women are Not Broken by Cherise Hamblin, MD and Ahnyia Sanders, MS:

[1] Organization for Economic Co-Operation and Development (2023, July 3). Health Status: Maternal and infant mortality. OCED.Stat. Retrieved October 26, 2023, from https://stats.oecd.org/index.aspx?queryid=30116

[2] Hoyert, D. L. (2023). Maternal Mortality Rates in the United States, 2021. National Center for Health Statistics. Retrieved October 26, 2023, from https://www.cdc.gov/nchs/data/hestat/maternal-mortality/2021/maternal-mortality-rates-2021.pdf

[3] Hoyert, D. L. (2023). Maternal Mortality Rates in the United States, 2021. National Center for Health Statistics. Retrieved October 26, 2023, from https://www.cdc.gov/nchs/data/hestat/maternal-mortality/2021/maternal-mortality-rates-2021.pdf

[4] Commonwealth of Massachusetts Department of Public Health (2023, July 1). Data Brief: An Assessment of Severe Maternal Morbidity in Massachusetts: 2011-2020. Mass.gov. Retrieved October 26, 2023, from https://www.mass.gov/doc/an-assessment-of-severe-maternal-morbidity-in-massachusetts-2011-2020/download

[5] What is a doula. DONA International. (2023, June 23). https://www.dona.org/what-is-a-doula-2/

[6] Sobczak, A., Taylor, L., Solomon, S., Ho, J., Kemper, S., Phillips, B., Jacobson, K., Castellano, C., Ring, A., Castellano, B., & Jacobs, R. J. (2023). The Effect of Doulas on Maternal and Birth Outcomes: A Scoping Review. Cureus, 15(5), e39451. https://doi.org/10.7759/cureus.39451

[7] Ehrenreich, B. (2010). Witches, Midwives, & Nurses (Second Edition) : A History of Women Healers, The Feminist Press at CUNY, 2010. ProQuest Ebook Central.

[8]https://nmaahc.si.edu/explore/stories/historical-significance-doulas-and-midwives

[9]https://www.midwife.org/why-we-need-more-midwives-of-color#:~:text=Black%20midwives%20make%20up%20only,Certified%20Midwives%20in%20the%20US.

[10] American Medical Association. AMA Physician Masterfile (Dec. 31, 2021). Race and ethnicity are obtained from a variety of AAMC sources, including DBS, ERAS, APP, MCAT, SMDEP, GQ, MSQ, PMQ, FACULTY, GME, and STUDENT, with priority given to the most recent self-reported source.

 

 

Misinformation and Manipulation: Exposing Crisis Pregnancy Centers by Zarah Rosen, MD:

  1. Raymond EG, Grimes DA. The comparative safety of legal Induced abortion and childbirth in the United States. Obstetrics and Gynecology. 2012;119(2 Pt 1):215-219. doi:https://doi.org/10.1097/AOG.0b013e31823fe923
  2. Committee on Gynecologic Practice. Committee opinion: Induced abortion and breast cancer risk. 434. The American College of Obstetricians and Gynecologists. 2009. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2009/06/induced-abortion-and-breast-cancer-risk. Accessed January 1, 2024.
  3. Abortion access fact sheet. The American College of Obstetricians and Gynecologists. https://www.acog.org/advocacy/abortion-is-essential/come-prepared/abortion-access-fact-sheet. Accessed January 1, 2024.
  4. Abortion and cancer risk. American Cancer Society. https://www.cancer.org/cancer/risk-prevention/medical-treatments/abortion-and-breast-cancer-risk.html. Accessed January 1, 2024.
  5. Abortion risks. National Health Service (UK). https://www.nhs.uk/conditions/abortion/risks/. Accessed January 1, 2024.
  6. Bixby Center for Global Reproductive Health. Introduction to the turnaway study chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.ansirh.org/sites/default/files/2022-12/turnawaystudyannotatedbibliography122122.pdf Published 2022. Accessed January 1, 2024.
  7. Find abortion care in Massachusetts. Reproductive Equity Now. https://reproequitynow.org/find-a-provider-massachusetts. Accessed December 30, 2023.
  8. Swartzendruber A and Lambert D. Crisis pregnancy center map. http://www.crisispregnancycentermap.com. Published August, 2021. Accessed: December 30, 2023.

 

 

Promoting the Health, Inclusion, and Belonging of Sexual and Gender Minorities in the Clinical Space by Olivia Buckle, BA:

Center, N. L. H. E. (2021). Ten Strategies for Creating Inclusive Health Care Environments for LGBTQIA+ People (2021). T. F. Institute. lgbtqiahealtheducation.org, The Fenway Institute.

Dahlen, S., et al. (2021). “International clinical practice guidelines for gender minority/trans people: systematic review and quality assessment.” BMJ Open 11(4): e048943.

James, S. E., Herman, J. L., Rankin, S., Keisling, M., Mottet, L., & Anafi, M. (2016). Executive Summary of the Report of the 2015 U.S. Transgender Survey. Washington, DC: National Center for Transgender Equality.

 

Pharmacological Advancements for Women’s Reproductive Health Transitions by Mary Fischer, PhD, WHNP-BC, MSCP, Audrey O’Neil, RN, David Runyan, FNP-BC, NRP, and Teri Aronowitz, PhD, FNP-BC, FAAN

  1. Hoyt, L.T. & Falconi, A.M. (2015). Puberty and perimenopause: Reproductive transitions and their implications for women’s health. Social Science & Medicine, 132, 103-113. http://dx.doi.org/10.1016/j.socscimed.2015.03.031
  2. Santoro, N., Roeca, C., Peters, B. A., & Neal-Perry, G. (2021). The Menopause Transition: Signs, Symptoms, and Management Options. The Journal of Clinical Endocrinology & Metabolism, 106 (1), 1- 15. https://doi.org/10.1210/clinem/dgaa764
  3. Pearlstein, T., Howard, M., Salisbury, A., & Zlotnick, C. (2009) Postpartum depression. American Journal of Obstetrics and Gynecology, 200(4): 357-64. https://doi.org/10.1016/j.ajog.2008.11.033
  4. De Baetselier, E., Dilles, T., Feyen, H., Haegdorens, F., Mortelmans, L., & Van Rompaey, B. (2022). Nurses’ responsibilities and tasks in pharmaceutical care: A scoping review. Nursing open, 9(6), 2562–2571. https://doi.org/10.1002/nop2.984
  5. Deligiannidis, K. M., Meltzer-Brody, S., Maximos, B., Peeper, E. Q., Freeman, M., Lasser, R., Bullock, A., Kotecha, M., Li, S., Forrestal, F., Rana, N., Garcia, M., Leclair, B., & Doherty, J. (2023). Zuranolone for the Treatment of Postpartum Depression. The American journal of psychiatry, 180(9), 668–675. https://doi.org/10.1176/appi.ajp.20220785
  6. Ghaedrahmati M., Kazemi, A., Kheirabadi, G., Ebrahimi, A., & Bahrami, M. (2017) Postpartum depression risk factors: A narrative review. Journal of Education and Health Promotion, (6) 60. DOI:10.4103/jehp.jehp_9_16
  7. Chin, K., Wendt, A., Bennett, I. M., & Bhat, A. (2022) Suicide and Maternal Mortality. Current Psychiatry Reports, 24(4):239-275. https://doi.org/10.1007/s11920-022-01334-3
  8. Suryawanshi, O., 4th, & Pajai, S. (2022) A Comprehensive Review on Postpartum Depression. Cureus. 14(12):e32745. https://doi.org/10.7759/cureus.32745.
  9. Aschenbrenner, D. (2023). First Oral Treatment for Postpartum Depression. AJN The American Journal of Nursing, 123(12), 16-17.
  10. Moore Simas TA, Whelan A, Byatt N. (2023). Postpartum Depression—New Screening Recommendations and Treatments. JAMA, 330(23):2295–2296. Https://doi.org/10.1001/jama.2023.21311
  11. Beninger, P. (2023). Zuranolone. Clinical therapeutics, 45(12), 1297-1298.
  12. Talaulikar, V. (2022). Menopause transition: Physiology and symptoms. Best Practice & Research Clinical Obstetrics & Gynaecology, 81, 3–7. https://doi.org/10.1016/j.bpobgyn.2022.03.003
  13. Avis, N. E., Crawford, S. L., & Green, R. (2018). Vasomotor symptoms across the menopause transition. Obstetrics and Gynecology Clinics of North America, 45(4), 629–640. https://doi.org/10.1016/j.ogc.2018.07.005
  14. Patel, B., & Dhillo, W. S. (2022). Menopause review: Emerging treatments for menopausal symptoms. Best Practice & Research Clinical Obstetrics & Gynaecology, 81, 134-144. https://doi.org/10.1016/j.bpobgyn.2021.10.010
  15. Conklin, M., & Santoro, N. (2023). Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause. Therapeutic Advances in Reproductive Health, 17, 1-8. https://doi.org/10.1177/26334941231177611
  16. Christ, J. P., Navarro, V. M., & Reed, S. D. (2023). Nonhormonal Therapies for Menopausal Vasomotor Symptoms. JAMA, 330(13), 1278-1279. https://doi.org/10.1001/jama.2023.15965
  17. Shufelt, C. L., Brown, V., Carpenter, J. S., Chism, L. A., Faubion, S. S., Joffe, H., Kling, J. M., Soares, C., & Thurston, R. C. (2023) The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause, 30(6), 573-590. https://doi.org/10.1097/GME.0000000000002200
  18. Javernick, J. A. (2023). A Novel Nonhormonal Treatment for Vasomotor Symptoms of Menopause. Nursing for Women’s Health. https://doi.org/10.1016/j.nwh.2023.11.005
  19. Mirin, A.A. (2021). Gender disparity in the funding of diseases by the U.S. National Institutes of Health. Journal of Women’s Health, 30(7), 956-963. https://doi.org/10.1089/jwh.2020.8682

 

 

New Innovations to Increase Contraception Access in Massachusetts by Katharine Nault, PharmD, MBA, BCCCP and Aimee Dawson, PharmD:

 

  1. FDA approves First Nonprescription Daily Oral Contraceptive. (2023, July 13). U.S. FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive
  2. FDA Briefing Document: Joint Meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee. (2023, May).  https://www.fda.gov/media/167892/download
  3. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016;65(No. RR-3). 10.15585/mmwr.rr6503a1.
  4. Progestin-Only Hormonal Birth Control: Pill and Injection. (2023, January). ACOG. https://www.acog.org/womens-health/faqs/progestin-only-hormonal-birth-control-pill-and-injection
  5. OPill FAQs. Perrigo. https://opillhcp.com/pages/faqs
  6. Webb JL. Nutritional effects of oral contraceptive use: a review. J Reprod Med. 1980;25(4):150-156.
  7. FDA allows marketing of first DTC app for contraceptive use to prevent pregnancy. (2018, August 10) U.S. FDA. https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-first-direct-consumer-app-contraceptive-use-prevent-pregnancy.
  8. Lavery, JG. Circular Letter: DCP 23-10-121. (2023, November 1) DPH. https://www.mass.gov/news/circular-letter-dcp-23-10-121#:~:text=M.G.L.,self%2Dadministered%20oral%20hormonal%20contraceptives